Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2026)
Contineum Therapeutics (CTNM) recorded quarterly Income from Continuing Operations of 14399000.0 in Q1 2026, up 4.67% quarter-over-quarter from 15105000.0 in Q4 2025, and up 9.21% on a YoY basis from 13184466.25 in Q1 2025.
Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 14399000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 9.21% year-over-year to 14399000.0; the TTM figure through Mar 2026 stood at 58352000.0 (down 17.41% YoY), while the FY2025 annual figure was 59813000.0, down 41.54% from the prior year.
- Income from Continuing Operations was 14399000.0 for Q1 2026 at Contineum Therapeutics, up from 15105000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 41600000.0 in Q2 2023 to a low of 15873000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 7210153.85 across 4 years, with a median of 10267000.0 in 2024.
- The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations sank 121.66% in 2024, then increased 9.21% in 2026.
- A 4-year view of Income from Continuing Operations shows it stood at 7769000.0 in 2023, then slumped by 87.48% to 14565000.0 in 2024, then slipped by 3.71% to 15105000.0 in 2025, then gained by 4.67% to 14399000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 14399000.0 (Q1 2026), 15105000.0 (Q4 2025), and 12975000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Contineum Therapeutics | 430.52 Mn | 430.52 Mn | - | -14.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.40 Mn |
| Dec 31, 2025 | -15.11 Mn |
| Sep 30, 2025 | -12.98 Mn |
| Jun 30, 2025 | -15.87 Mn |
| Mar 31, 2025 | -15.86 Mn |
| Dec 31, 2024 | -14.57 Mn |
| Sep 30, 2024 | -10.27 Mn |
| Jun 30, 2024 | -9.01 Mn |
| Mar 31, 2024 | -8.42 Mn |
| Dec 31, 2023 | -7.77 Mn |
| Sep 30, 2023 | -6.27 Mn |
| Jun 30, 2023 | 41.60 Mn |
| Mar 31, 2023 | -4.82 Mn |